6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-26), Acorda Therapeutics's 6-1 Month Momentum % is 19.65%.
The industry rank for Acorda Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
ACORQ's 6-1 Month Momentum % is ranked better than 70.11% of 1114
companies
in the Drug Manufacturers industry
Industry Median: 1.805
vs ACORQ: 19.65
Competitive Comparison of Acorda Therapeutics's 6-1 Month Momentum %
For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acorda Therapeutics's 6-1 Month Momentum % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Acorda Therapeutics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Acorda Therapeutics 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Acorda Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Acorda Therapeutics (Acorda Therapeutics) Business Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACORQ has been successfully added to your